Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.

Abstract

These results identify a novel association between MMP-9 activation and primary GBM subtype and suggest that primary GBM patients, especially those whose tumors express EGFRvIII, may benefit from anti-MMP therapy.